非感染性葡萄膜炎的免疫调节治疗:现状、差距与未来方向
本文综述非感染性葡萄膜炎(NIU)中免疫调节治疗(IMT)的当前角色,重点为减少糖皮质激素用量的策略;涵盖传统免疫抑制剂、生物制剂、小分子药物及干扰素类治疗,并讨论IMT在治疗流程中的位置、早期启动的新证据及靶向与个体化免疫治疗等未来方向。
要点
- 糖皮质激素虽可快速抑制炎症,但长期使用受显著全身和眼部副作用限制。
- IMT包括抗代谢药、钙调神经磷酸酶抑制剂、生物制剂和新兴小分子药物,已成为慢性病例实现持续控制并减少激素负担的核心。
- 安全且能诱导缓解的治疗仍难以实现,减量策略标准化不足,最佳联合方案或长期结局证据仍有限。
核心结论
- 本综述总结IMT在NIU管理中的当前作用,强调减少糖皮质激素用量的策略,并探讨靶向与个体化免疫治疗的未来方向。
研究设计与样本
- 综述类文章,检索范围未在摘要中报告。
主要发现
- 安全且能诱导缓解的治疗仍难以实现;减量策略标准化不足;最佳联合方案或长期结局的证据仍有限。
- PROTON和TOFU等注册研究正开始满足对结构化治疗退出框架的未满足需求。
- 影像学和人工智能的进展可能很快实现疾病状态实时监测和风险分层,但开发可供此类分析的大型、注释完善的队列仍是关键障碍。
局限性
- 安全、能诱导缓解的治疗仍难以实现。
- 减量策略标准化不足。
- 最佳联合方案或长期结局的证据仍有限。
- 开发可供影像学和人工智能分析的大型、注释完善的队列仍是关键障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-infectious uveitis (NIU) is a potentially sight-threatening intraocular inflammatory condition that may arise idiopathically or in association with systemic immune-mediated diseases. While corticosteroids remain essential for rapid suppression of inflammation, their long-term use is limited by significant systemic and ocular side effects. Thus, immunomodulatory therapy (IMT)-including antimetabolites, calcineurin inhibitors, biologics, and emerging small molecules-has become central to achieving sustained control with a reduced corticosteroid burden in chronic cases. Despite a range of therapeutic options, significant challenges persist. Safe, remission-inducing treatments remain elusive; tapering strategies are poorly standardized; and evidence for optimal combinations or long-term outcomes remains limited. Recent registries, such as Programme for Ocular Inflammation and Infection Translational Research (PROTON) and Treatment Exit Options for Uveitis (TOFU), are beginning to address the unmet need for structured treatment exit frameworks. Moreover, advances in imaging and artificial intelligence may soon enable real-time monitoring of disease status and risk stratification, although the development of large, well-annotated cohorts to be subject to such analysis remains a key hurdle. This review summarizes the current role of IMT in the management of NIU, with an emphasis on corticosteroid-sparing strategies. We highlight the use of conventional immunosuppressants-including antimetabolites, calcineurin inhibitors, and alkylating agents-as well as newer biologic, smallmolecule, and interferon-based therapies. We outline where IMT fits within the broader treatment algorithm, discuss emerging evidence for earlier initiation, and explore future directions in targeted and personalized immunotherapy. We also explore future directions, including personalized approaches, biomarker-driven therapy, and the promise of AI-guided prediction models.
引用
- Agrawal R, Goh YY, Rojas-Carabali W, et al. Immunomodulatory therapy in non-infectious Uveitis: Current landscape, gaps, and future directions. Prog Retin Eye Res. 2025. PMID: 40550324. doi:10.1016/j.preteyeres.2025.101380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。